紫杉醇联合顺铂在治疗晚期食道癌患者的临床应用疗效研究

Clinical Application Efficacy of Paclitaxel Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer

目的研究和探讨紫杉醇和顺铂在治疗晚期食道癌中的临床效果。方法选取2011年2月—2014年1月该院收治的123例处于晚期的食道癌患者作为研究对象,按照化疗的方案不同分成观察组（51例）和对照组（72例）。观察组患者给予紫杉醇加顺铂的治疗,对照组患者给予5氟尿嘧啶加顺铂进行治疗。分析对比两组所收的治疗效果。结果观察组和对照组患者的有效率分别为54.91%和48.61%,两组总有效率对比,其差异无统计学意义（χ^2=0.335,P〉0.05）;经过6-45个月随访,观察组患者的TTP与MST值分别为（6.6±1.4）、（10.3±2.1）月,明显高于对照组患者,两组患者的TTP与MST值对比,差异有统计学意义（P〈0.05）。结论对于晚期食道癌患者,采用紫杉醇联合顺铂进行治疗,疗效显著,而且能明显延缓肿瘤进展的时间,并延长癌症患者的生存期,因此,可以在临床治疗中大力推广。

Objective To study and investigate the clinical effect of Paclitaxel combined with Cisplatin in the treatment of ad-vanced esophageal cancer. Methods 123 patients with advanced esophageal cancer admitted to our hospital from 2011 February to 2014 January were selected as the subjects and divided into the observation group （51 cases） and the control group （72 cases） in accordance with the chemotherapy regimen. Patients in the observation group were treated by Paclitaxel combined with Cisplatin, while those in the control group were treated by 5-Fluorouracil combined with Cisplatin. And the therapeutic effects of the two groups were analyzed and compared. Results The response rate of the observation group and the control group was 54.91% and 48.61%, respectively, the difference between the two groups was not statistically significant （x2=0.335, P〉0.05）. The result of 6-45 months follow-up showed that the value of TTP and MST of the observation group was （6.6±1.4） months,（10.3±2.1） months, re-spectively, much longer than that of the control group, respectively, the differences between the two groups were statistically signifi-cant（P〈0.05）. Conclusion For patients with advanced esophageal cancer, Paclitaxel combined with Cisplatin has remarkable cura-tive effect, which can significantly delay the tumor progression time, and prolong the survival of cancer patients, therefore, it can be popularized in clinical treatment.